Clinical Trial Update: Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated switching to natalizumab in participants with relapsing multiple sclerosis after failure on other therapies; the study was terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing Multiple Sclerosis | Phase 4 | Status: TERMINATED | Results posted: 2017-06-05